Evolus (EOLS) Total Current Liabilities (2017 - 2026)
Evolus (EOLS) reported Total Current Liabilities of $68.0 million for Q1 2026, up 20.97% on a YoY basis from $56.2 million in Q1 2025, and down 9.67% quarter-over-quarter from $75.3 million in Q4 2025.
Evolus (EOLS) Total Current Liabilities (2017 - 2026) Analysis & Trends
Evolus has reported Total Current Liabilities for 10 years, with the latest figure at $68.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 20.97% year-over-year to $68.0 million; the trailing twelve-month figure through Mar 2026 stood at $68.0 million (up 20.97% YoY), and the FY2025 full-year result was $75.3 million, up 19.61% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $68.0 million, down from $75.3 million in the prior quarter.
- The five-year high for Total Current Liabilities was $75.3 million in Q4 2025, with the low at $40.7 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $54.3 million across 5 years, with a median of $51.5 million in 2022.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 53.56% — and 2024, when it surged 30.88%.
- Evolus' Total Current Liabilities stood at $46.5 million in 2022, then increased by 3.83% to $48.3 million in 2023, then surged by 30.38% to $63.0 million in 2024, then gained by 19.61% to $75.3 million in 2025, then fell by 9.67% to $68.0 million in 2026.
- The last three Total Current Liabilities figures came in at $68.0 million (Q1 2026), $75.3 million (Q4 2025), and $66.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.53 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 2.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 831.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 1.66 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 599.50 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 618.78 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 333.17 Mn |
| 10 | Evolus | 437.40 Mn | 387.61 Mn | 48.90 Mn | 68.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.02 Mn |
| Dec 31, 2025 | 75.31 Mn |
| Sep 30, 2025 | 66.71 Mn |
| Jun 30, 2025 | 63.75 Mn |
| Mar 31, 2025 | 56.23 Mn |
| Dec 31, 2024 | 62.96 Mn |
| Sep 30, 2024 | 60.82 Mn |
| Jun 30, 2024 | 54.12 Mn |
| Mar 31, 2024 | 46.80 Mn |
| Dec 31, 2023 | 48.29 Mn |
| Sep 30, 2023 | 48.54 Mn |
| Jun 30, 2023 | 41.35 Mn |
| Mar 31, 2023 | 40.68 Mn |
| Dec 31, 2022 | 46.51 Mn |
| Sep 30, 2022 | 51.27 Mn |
| Jun 30, 2022 | 51.53 Mn |
| Mar 31, 2022 | 40.70 Mn |
| Dec 31, 2021 | 57.66 Mn |
| Sep 30, 2021 | 71.30 Mn |
| Jun 30, 2021 | 87.29 Mn |